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Abstract
Introduction
Comparing multiple, diverse outcomes with cost-effectiveness analysis (CEA) is important,
yet challenging in areas like palliative care where domains are unamenable to integration
with survival. Generic multi-attribute utility values exclude important domains and non-
health outcomes, while partial analyses—where outcomes are considered separately, with
their joint relationship under uncertainty ignored—lead to incorrect inference regarding
preferred strategies.
Objective
The objective of this paper is to consider whether such decision making can be better in-
formed with alternative presentation and summary measures, extending methods previous-
ly shown to have advantages in multiple strategy comparison.
Methods
Multiple outcomes CEA of a home-based palliative care model (PEACH) relative to usual
care is undertaken in cost disutility (CDU) space and compared with analysis on the
cost-effectiveness plane. Summary measures developed for comparing strategies across
potential threshold values for multiple outcomes include: expected net loss (ENL) planes
quantifying differences in expected net benefit; the ENL contour identifying preferred strate-
gies minimising ENL and their expected value of perfect information; and cost-effectiveness
acceptability planes showing probability of strategies minimising ENL.
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Results
Conventional analysis suggests PEACH is cost-effective when the threshold value per addi-
tional day at home ( 1) exceeds $1,068 or dominated by usual care when only the propor-
tion of home deaths is considered. In contrast, neither alternative dominate in CDU space
where cost and outcomes are jointly considered, with the optimal strategy depending on
threshold values. For example, PEACH minimises ENL when 1=$2,000 and 2=$2,000
(threshold value for dying at home), with a 51.6% chance of PEACH being cost-effective.
Conclusion
Comparison in CDU space and associated summary measures have distinct advantages to
multiple domain comparisons, aiding transparent and robust joint comparison of costs and
multiple effects under uncertainty across potential threshold values for effect, better inform-
ing net benefit assessment and related reimbursement and research decisions.
Introduction
Conventional cost-effectiveness analysis (CEA) is limited to consideration of one measure of
effect such as life years gained [1]. However, when multiple outcome domains are important
such single outcome comparison can lead to conflicting conclusions concerning preferred
strategies [2, 3]. Consequently, decisions about the costs and benefits of funding allocations
can be misinformed and lead to inefficient distribution of finite health care resources [2, 4].
The widely applied quality-adjusted life year (QALY) measure overcomes this limitation to
the extent that impacts on multiple domains of health can be integrated with survival [1]. How-
ever, QALYs calculated using generic multi-attribute utility instruments (MAUIs) such as the
EQ-5D [5] focus upon health alone as the sole indicator of value. Empirical studies have shown
that individuals may also gain utility from factors relating to the provision of health care [6–8].
Economic analyses focusing on health alone do not enable robust coverage of the impacts of in-
terventions in complex disease areas where multiple, diverse domains of effect are important.
For example, in palliative care, many patients obtain value from receiving home-based rather
than hospital care [9].
In palliative care, the use of the QALY measure is also limited by the:
1. omission of important patient-valued domains from generic MAUIs, such as preparation
for death and existential issues [10, 11];
2. changes in patient and clinical perspective due to the proximity of death when valuing
utility;
3. dearth of palliative care specific utility instruments incorporating the key domains impor-
tant to patients receiving palliative care [12];
4. limited availability of suitable palliative care quality of life (QOL) measurement tools to
‘map’ to common MAUIs; and
5. the inability to integrate the impacts on carers’ utility, survival and willingness to care
[3, 13, 14].
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One option might be to develop a condition-specific MAUI to incorporate palliative care-
related effects of interest. Naturally, this would require identifying salient health and non-
health related QOL domains and items for inclusion within each domain. Furthermore,
confirmation of the content and construct validity and responsiveness of the condition-specific
MAUI would be necessary [15]. However, such research would be expected to take years to
complete and still faces issues of how to weight or combine effects to inform societal decision
making with the objective of maximising budget constrained net benefit (NB) across research,
reimbursement and regulation decisions [16]. Alternatively, cost-consequences analysis (CCA)
[1] with disaggregated mean costs and multiple outcomes explicitly presented has been advo-
cated as a preferred method in these situations [17, 18]. However, in CCA, cost and multiple
outcomes are treated separately without consideration of their interaction or joint uncertainty.
As Briggs et. al. argue in seminal papers on the death of cost-minimisation [19], and cost ef-
fectiveness under uncertainty [20], separate and sequential hypothesis tests on differences in
outcomes and costs lead to fallacious inferences. It is important that CEA represents joint un-
certainty associated with cost and outcomes so that funders and policy makers can make valid
inferences and optimise across joint research, reimbursement, regulation and pricing decisions
[16, 21, 22]. Jointly evaluating costs with multiple effects and their potential values under un-
certainty would enable robust and transparent trade offs between impacts of strategies and the
NB of strategies under uncertainty and hence aid consideration of the consequences of reim-
bursement decisions. Further, if summary measures representing the expected value of perfect
information were developed, these measures could start to address decisions related to the
value of conducting future research relative to the cost of obtaining the additional information
[16, 21, 23]. Ultimately, economic evaluations can easily misrepresent the relative NB of pallia-
tive and end-of-life care without simultaneous consideration of costs and multiple outcome do-
mains under uncertainty. Accessible, robust and generalisable methods for jointly comparing
cost and multiple outcomes under uncertainty consistent with budget constrained maximisa-
tion of NB are needed to better inform funding decisions in such settings.
For multiple strategy comparisons Eckermann et al. [24–26] demonstrate distinct decision
making advantages of: (i) presenting costs and effects on the cost-disutility (CDU) plane, with
effects framed from a utility reducing perspective, e.g. mortality, morbidity or reduction in
QALYs, and flexible axes where costs and effects are measured relative to the least costly and
most effective strategies respectively; and (ii) simply calculated expected net loss (ENL) curves
and frontiers for each strategy which identify both the optimal strategy in minimising ENL at
any threshold value and their expected value of perfect information (EVPI). This paper extends
these methods to consider multiple outcomes under uncertainty and whether and how such
comparison can be used to better inform societal decision making when optimising budget
constrained NB.
The next section summarises conventional CCA and CEA applied to compare multiple out-
comes with alternative palliative care models. The new methodology, multiple outcomes com-
parison in CDU space, and associated summary measures are then introduced and illustrated.
The relative merits of these alternative methods for multiple outcomes CEA are discussed in
palliative care settings and more generally with multi-criteria decision analysis (MCDA) and fi-
nally conclusions and implications are drawn.
Methods
The cost effectiveness of a home-based palliative care model (Palliative Care Extended Pack-
ages at Home (PEACH)) which aimed to expedite discharge and enable patients to remain at
home is evaluated relative to usual care using participant-level data from a pilot study. Full
Multiple Outcome Cost-Effectiveness Analysis in Cost-Disutility Space
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details of the economic evaluation are presented elsewhere [27]. Ethics approval for the pilot
study was granted by Sydney South West Area Health Service Human Research Ethics Com-
mittees. Written informed consent was obtained from the pilot study participants.
Cost-consequences and cost-effectiveness analyses
Mean incremental per patient effects and net costs were calculated for PEACH relative to usual
care including: days at home; place of death; PEACH intervention costs; costs of specialist palli-
ative care service use; and costs of acute hospital and palliative care unit inpatient stays and
outpatient visits. Net benefit (Equation 1) was calculated to address analytical and inferential
shortcomings of the incremental cost-effectiveness ratio (ICER), while retaining the same un-
derlying cost effectiveness objective [20, 28–31]. Under the NB approach, an intervention is
considered cost- effective if, at specified decision-maker threshold values, the monetary value
of the incremental effects is greater than the incremental costs i.e., incremental net benefit
(INB) is positive (see Equation 2) [24]. The intervention with the greatest INB is considered
the most cost-effective in multiple intervention comparison. In budget constrained health sys-
tems, threshold values for effects should be the health shadow price for a unit gain of effect re-
flecting opportunity cost and maximisation of health system outcomes, i.e. represent the best
alternative way of achieving the same effects [22, 32–34].
NB1 ¼  E1  C1 Equation 1
ðE1  E0Þ  ðC1  C0Þ > 0 Equation 2
where, 1 = evaluated intervention, 0 = comparator, C = cost, E = effectiveness and k = the
threshold value.
INB and cost-effectiveness acceptability curves (CEACs) were estimated at potential thresh-
old values for one extra day at home, the primary outcome [31, 35]. Uncertainty for costs, ef-
fects and cost effectiveness were estimated bootstrapping on participants’ costs and effects
pairs across 10,000 replicates.
Comparison on the cost-disutility plane
Net benefit correspondence theorem (NBCT). Eckermann [36] and Eckermann, Briggs
andWillan [24] demonstrated a one to one correspondence between (i) maximising NB and
(ii) minimising costs and the decision maker’s value of events from a utility-reducing perspec-
tive. Applying this approach, the equation for INB (Equation 2) [28] is transformed into the
following,
INBi ¼ ð  DUi þ CiÞ  ð  DU þ CÞ Equation 3
where DU are effects framed from a disutility perspective, C represents costs, i represents the
strategy under consideration and  is the optimal strategy at threshold value for a unit of effect.
Radial efficiency measures on the CDU plane. Reframing effects from a utility-reducing
perspective and comparing strategies on the CDU plane allows NB improvement with contrac-
tion to the vertex; that is performance improves with equi-proportionally contraction of costs
and effects to the origin. Importantly, these radial properties enable efficiency measures invari-
ant to scale of axes, unlike non-radial efficiency measures [37] and allow conventional econom-
ic, technical and allocative efficiency measures [22–24, 29] to be calculated using standard
frontier estimation methods such as data envelopment analysis (DEA) or index methods. Gen-
erally, employing input-orientated DEA, a piecewise, convex, inner-boundary is formed
Multiple Outcome Cost-Effectiveness Analysis in Cost-Disutility Space
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reflecting combinations of multiple inputs that cannot be proportionally contracted with the
feasible set (convex combination of other strategies) [38].
Farrell [37], in 1957, also showed radial properties enable economic efficiency to be express-
ed as the product of technical and allocative efficiency [37]. Hence when factor prices are ap-
plied [38] efficiency can be calculated [24, 26, 36] and decomposed into technical and
allocative efficiency components. In Fig. 1, BB’ represents possible combinations of inputs for a
given cost. S’ represents an allocatively efficient point because this lies on the production possi-
bilities frontier with minimal cost given factor prices, i.e. is using the appropriate mix of inputs
given input prices to produce the given output. Allocative inefficiency at point T is represented
by RS/0S. That is, the amount by which production costs can be reduced if the ratio of inputs
used by the firm at point T were identical to those used by the firm at point S’, the technically
and allocatively efficient firm [37].
Traditionally results presented graphically on the cost-effectiveness plane use a fixed com-
parator with improved performance indicated by south-east movement. Further, with multiple
strategy comparison, the point of reference changes along the efficiency frontier [24]. The use
of standard frontier estimation methods are prevented on the cost-effectiveness plane by the
absence of radial properties.
For multiple strategies with a single effect, Eckermann et al [24, 25] show that comparison
at potential threshold value for effects on the CDU plane naturally leads to considering the net
loss (NL) statistic for strategies, the expected net loss (ENL) relative to the strategy maximising
NB, ENL curves for each strategy and the ENL frontier as the lower bound of ENL curves.
In this paper use of DEA in CDU space is also shown to facilitate explicit and robust consid-
eration of the interaction of uncertainty between costs andmultiple outcomes and lead to use-
ful summary measures including:
1. Threshold regions, combinations of threshold values for joint outcomes where alternative
service models maximise NB [38].
2. ENL planes which quantify differences in ENL [28] across threshold values for multiple out-
comes, (i) time at home and (ii) death at home rather than in an inpatient setting;
3. The ENL contour which identifies the service model that minimises ENL across bootstrapped
replicates for combinations of threshold values across multiple outcomes [24, 25]; and
Fig 1. Farrell’s production possibilities frontier for two inputs and one output (adapted from Coelli
[41].
doi:10.1371/journal.pone.0115544.g001
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4. Cost-effectiveness acceptability planes which show the probability of each service model
minimising ENL at given combinations of value of effects for multiple outcomes.
Comparison in cost-disutility space
Technical efficiency frontier. The technical efficiency frontier was constructed using
DEA with a Farrell input-orientated technical efficiency model run under constant returns to
scale [39]. Mean incremental cost relative to the cheapest model of care and mean incremental
effects relative to the most effective model of care framed from a disutility perspective were in-
cluded as strongly disposable inputs. The resulting frontier identifies service models that mini-
mise cost for given effects framed from a disutility perspective [24–25, 36]. A technical
efficiency score of one indicates that service models form part of the technical efficiency fron-
tier and minimise costs for given effect rates at some combination of threshold values. Techni-
cal efficiency scores less than one indicate the model of care is dominated or extended
dominated by the other strategies and does not form part of the frontier, i.e. is technically inef-
ficient. In other words, both cost and disutility of effects can be equi-proportionally reduced
relative to a given strategy or convex combinations of other strategies.
Deterministic cost effectiveness analyses. To determine threshold regions where alterna-
tive models of care are preferred, NL is first calculated from incremental analysis in CDU
space. Applying the net benefit correspondence theorem [24], the objective of maximising NB
is equivalent to minimising NL. The NL of any given model of care (i) is the loss in NB from
choosing i rather than the optimal model of care () at given threshold value k for one effect
and can be found as follows:
NLi ¼ ð  DUi þ CiÞ  ð  DU þ CÞ Equation 4
where DU is the outcome framed from a utility-reducing perspective and C represents costs.
This relationship can be extended to include multiple outcomes [38]. For example, for two
outcomes and two strategies, i and j:
NLi ¼ ðð 1  DUi1Þ þ ð 2  DUi2Þ þ CiÞ  ðð 1  DU1Þ þ ð 2  DU2Þ þ C Equation 5
NLj ¼ ðð 1  DUj1Þ þ ð 2  DUj2Þ þ CiÞ  ðð 1  DU1Þ þ ð 2  DU2Þ þ C Equation 6
With deterministic analysis the preferred model of care is the model which minimises mean
NL at any given combination of threshold values, i.e. C + DU1 1 + DU2 2 is minimised. There-
fore, strategy i is preferred to strategy j when the mean NL of i is lower than the mean NL of j,
and vice versa. To find the regions where alternative models of care are preferred, the boundary
of the regions is first determined by equating the NL expressions for adjacent compared strate-
gies on the frontier in CDU space, and solving for 1 and 2, i.e.
Ci þ ð 1  DUi1Þ þ ð 2  DUi2Þ ¼ Cj þ ð 1  DUj1Þ þ ð 2  DUj2Þ Equation 7
Values either side of the boundary readily identify the combinations of potential threshold
values where each model minimises the mean NL.
Stochastic cost-effectiveness analyses (accounting for joint uncertainty). Bootstrapping
methods allow modelling of uncertainty across the joint distribution of incremental costs and
multiple incremental outcomes from the participant-level data, allowing for covariance be-
tween costs and effects [40]. The following measures are calculated using the bootstrap repli-
cates and summarise the expected return on investment and risk of return across potential
threshold values for multiple outcomes given current uncertainty.
Multiple Outcome Cost-Effectiveness Analysis in Cost-Disutility Space
PLOS ONE | DOI:10.1371/journal.pone.0115544 March 9, 2015 6 / 19
Choosing a strategy that does not minimise the NL incurs an incremental NL relative to the
optimal strategy. For each service model, at a given set of threshold values the NL relative to
the NB maximising strategy in each replicate is calculated and averaged across 10,000 replicates
to estimate ENL [24]. An expected loss arises for the proportion of replicates in which the ser-
vice model does not maximise the NB at the specified threshold values, reflecting decision un-
certainty given current trial evidence.
As in the case of ENL curves for a single effect [22], ENL planes quantify differences in ENL
across models of care for different combinations of values for effects. ENL planes are formed
by varying the threshold values for the multiple effects and re-calculating the average ENL
across replicates for each model of care. The distance between planes represents the difference
in ENL between models of care at any set of threshold values for effects under uncertainty [24].
The contour is formed by the lower bound of the ENL planes across models of care, i.e. the
lowest ENL values at combinations of threshold values are determined from consideration of
both planes, analogous to the ENL frontier as the lower bound of ENL curves [16, 24]. The con-
tour readily identifies the service model that minimises ENL for any set of values [22] for 1
and 2in the case of the PEACH study.
The expected value of perfect information (EVPI) is the loss from a bad decision that could
be avoided with perfect, rather than current information [21]. As with the ENL frontier, the
ENL contour naturally represents the EVPI per patient associated with choosing the strategy
minimising ENL [16, 24] given current uncertainty, but as a function of threshold values for
multiple rather than single effects.
Cost-effectiveness acceptability planes (CEAPs) show the probability that each model of
care minimises ENL conditional on threshold values for multiple effects. For each model of
care, the CEAP is formed by determining the proportion of replicates that minimise ENL for
different combinations of threshold values for effects.
Results
Cost-consequences and cost-effectiveness analyses
A summary of the trial-based incremental costs and consequences framed from a utility per-
spective are presented in Table 1. INB curves and CEACs are presented in McCaffrey et al [27].
PEACH is the preferred service model when the threshold value for one extra day at home ( 1)
exceeds $1,068 as the value of expected incremental benefits exceeds expected incremental
costs. However, the CCA suggests PEACH is dominated by usual care when the proportion of
home deaths is considered.
Analysis in cost-disutility space
A summary of the trial-based incremental costs and consequences framed from a utility-reduc-
ing perspective are presented in Table 2. The mean incremental cost relative to the cheapest
model of care and mean incremental effects framed from a disutility perspective relative to the
most effective model of care are calculated for each service model. For example, when consider-
ing incremental inpatient days, the mean incremental effect for PEACH is zero because
PEACH is the most effective model of care (14.9–14.9). Similarly, as usual care is the cheapest
model of care, the mean incremental cost for usual care is zero ($5,425—$5,425).
Technical efficiency frontier. Both models of care are part of the technical efficiency fron-
tier in CDU space where costs and multiple outcomes are considered (Fig. 2), i.e. both models
of care minimise NL for some set of threshold values for time spent at home and place of
death. The frontier in CDU space (line A-B in Fig. 2) represents the inner bound of linear
Multiple Outcome Cost-Effectiveness Analysis in Cost-Disutility Space
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combinations of service models closest to the origin, i.e. those minimising ENL at different
combinations of threshold values for effects.
Threshold regions. Following the incremental analysis in CDU space (Table 2), the mean
NL for each model of care can be expressed as follows (see Equation 7):
Table 1. Summary of incremental costs and outcomes framed from a utility perspective at 28 days for PEACH versus usual care.
PEACH Usual Care Increment
(n = 23)1 (n = 8)
Consequences, mean (95% CI2)
Number of days at home 13.09 12.13 0.96
(8.52, 17.65) (5.88, 18.38) (-6.79, 8.64)
Proportion of participants who died, % 69.57 62.50 7.07
(52.17, 86.96) (25.00, 100) (-45.11, 30.43)
Of those who died, the proportion of home deaths % 56.25 80.00 -23.75
(31.25, 80.00) (33.33, 100) (-63.16, 25.00)
Costs, mean (95% CI2)
PEACH $3,489 0 $3,489
($2,170, $4,943) ($2,170, $4,943)
Specialist palliative care services $361 ($256, $470) $372 ($229, $526) -$11 (-$196, $168)
Inpatient stay3 $2,603 $5,053 -$2,450
($1,205, $4,147) ($2,084, $8,139) (-$5,843, $957)
Total $6,452 $5,425 $1,027
($,4,469, $8,586) ($2,404, $8,531) (-$2,612, $4,738)
Threshold value4 above which the mean INB becomes positive (95% CI) $1,068
(-$6,627, $6,578)
1 one participant in the PEACH arm was excluded from the analysis due to incomplete cost data;
2 calculated with bootstrap analysis;
3 hospital or palliative care unit;
4 for one extra day at home
doi:10.1371/journal.pone.0115544.t001
Table 2. Summary of incremental costs and outcomes framed from a disutility perspective at 28 days for PEACH versus usual care.
Model of care Increment
PEACH Usual Care PEACH Usual Care
(n = 23)1 (n = 8)
Consequences, mean (95% CI2)
Number of inpatient days 14.91 15.88 03 0.963
(10.35, 19.48) (9.63, 22.13) (0, 6.78) (0, 8.64)
Of those who died, the proportion of inpatient deaths, % 43.75 20.00 23.753 03
(20.00, 68.75) (0, 66.67) (0, 63.16) (0, 25.00)
Costs, mean (95% CI2) $6,452 $5,425 $1,0274 $04
($4,469, $8,586) ($2,404, $8,531) (0, $4,738) (0, $2,612)
1 one participant in the PEACH arm was excluded from the analysis due to incomplete cost data;
2 calculated with bootstrap analysis;
3 relative to the most effective model of care (DU1i-DU1*);
4 relative to the cheapest model of care (Ci-C*)
doi:10.1371/journal.pone.0115544.t002
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i. Usual care, NL = $0 + 0.96 1 + 0 2 = 0.96 1; and
ii. PEACH, NL = $1,027 + 0 1 + 0.24 2 = $1,027 + 0.24 2
Where 1 is the threshold value for one extra day at home over 28 days and 2 is the threshold
value for one extra home death over 28 days.
Equating the NL expressions determines the boundary between regions of threshold value
combinations where each model of care is preferred, represented by the line in Fig. 3.
PEACH is preferred to usual care when the mean NL of PEACH is lower than the mean NL
of usual care, i.e. $1,027 + 0.24 2< 0.96 1, simply rearranged to 1> 0.25 2 + $1,068. Hence,
for example when threshold values for both an extra day at home ( 1) and home deaths ( 2)
are $2,000, PEACHminimises NL and is the preferred model of care; point A in Fig. 3. Con-
versely, when 1 = $2,000 and 2 = $4,000, usual care is preferred (point B, Fig. 3). This high-
lights that neither alternative dominated the other in CDU space when incremental cost, days
at home and the proportion of home deaths are jointly considered.
Expected net loss planes. Fig. 4 shows a two dimensional representation of the ENL
planes for PEACH and usual care. The threshold value per extra day at home is represented
Fig 2. Technical efficiency frontier in cost-disutility space for PEACH and usual care.
doi:10.1371/journal.pone.0115544.g002
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along the x-axis and the mean ENL per patient on the y-axis. Using the previous example,
when 1 = $2,000 and 2 = $2,000, PEACHminimises the ENL with an average loss in ex-
pected NB of $3,004 per participant. This loss arises as there are a proportion of replicates
(4,838/10,000) in which PEACH does not maximise the NB at these threshold values. At these
same values the ENL per patient if usual care is adopted is $3,354. If 1 = $2,000 and
2 = $4,000 the ENL per patient increases to $3,301 for PEACH and reduces to $3,172 for
usual care. The distance between planes represents the difference in per patient ENL between
models of care at any set of threshold values for effects under uncertainty [24]. For example,
Fig 3. Threshold regions over which each service model is preferred.
doi:10.1371/journal.pone.0115544.g003
Fig 4. Expected net loss planes (two dimensional representation).
doi:10.1371/journal.pone.0115544.g004
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when 1 = $2,000 and 2 = $2,000 the mean ENL per patient if PEACH is adopted is $3,004
and $3,354 if usual care is chosen, with a difference in ENL of $350 per patient.
Expected net loss contour. Fig. 5 is a two dimensional representation of the ENL contour
which is formed by the lower bound of the ENL planes across models of care (see Figs. 4 and 5)
[16, 24]. The dotted line indicates the combinations of 1 and 2, where usual care minimises
the ENL, whereas the solid line illustrates combinations of 1 and 2 where PEACHminimises
the ENL. Using the previous example, if 1 = $2,000 and 2 = $2,000, PEACHminimises the
ENL at $3,004 per participant across 10,000 replicates. When 1 = $2,000 and 2 = $4,000,
usual care minimises the ENL. Furthermore, in the latter scenario choosing usual care mini-
mizes ENL at $3,172 but given current uncertainty, PEACHminimizes ENL in 4,905/10,000
replicates. This loss of $3,172 per participant from choosing usual care would be avoided with
perfect information as the decision-maker would be able to pick the service model minimizing
ENL in each realisation.
Cost-effectiveness acceptability planes. Fig. 6 shows the CEAPs which represents the
probability that the strategy under consideration minimizes ENL at given combinations of
value of effects for multiple outcomes. For example, when 1 = $2,000 and 2 = $4,000 there is
a 49.05% chance that PEACH is the preferred option because PEACHminimizes ENL in
4,905/10,000 replicates.
Discussion
When assessing the cost effectiveness of interventions with multiple outcomes, presentation in
CDU space and use of ENL planes and contours to summarise cost effectiveness has been illus-
trated to overcome limitations of conventional CEA and CCA analysis. Partial analysis, where
individual outcomes and costs are considered separately, suggested PEACH is associated with
higher costs and increased benefits over 28 days relative to usual care when time spent at home
was the sole measure considered. However, PEACH was dominated by usual care when the
proportion of home deaths alone was considered. These results illustrate that choice of effect
where analysis is restricted to single effect substantially alters cost-effectiveness inferences. In
Fig 5. Expected net loss contour (two dimensional representation).
doi:10.1371/journal.pone.0115544.g005
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comparison, neither service model dominated in CDU space, when incremental cost and mul-
tiple outcomes were jointly considered. Compared with CCA the proposed approach has dis-
tinct advantages in allowing for joint uncertainty of incremental cost and outcomes, and cost
effectiveness. If societal decision making asymptotes to risk neutrality [26, 41] then findings
suggest PEACHmaximises expected NB when 1> 0.25 2 + $1,068. If preferences are some-
what risk-averse, trade-offs may also arise between minimising ENL and maximising the prob-
ability of minimising ENL across compared strategies for discrete regions of threshold values.
This paper extends previous work showing advantages of the CDU plane for comparing
multiple strategies. Cost and multiple effects of alternative models of care are clearly presented
in CDU space, facilitating identification, presentation and exploration of trade-offs between ef-
fects. Collectively, the new summary measures compared expected NB between strategies
across any set of feasible threshold values for multiple effects and the impact of joint uncertain-
ty. Threshold regions display the combinations of values over which alternative models of care
minimise mean NL or equivalently maximise NB. ENL planes present differences in ENL be-
tween alternatives, while the ENL contour simultaneously establishes: (i) the intervention that
minimises ENL; and (ii) EVPI with current evidence. Finally, CEAPs estimate the probability
that interventions minimise ENL. This may be of particular interest across discrete threshold
regions where the model of care with the lowest ENL does not have the greatest probability of
minimising ENL if societal decision making remains somewhat risk averse [41]. However, it
should be stressed that CEAPs, like CEACs, do not directly identify the strategy that minimises
ENL [25], unlike ENL planes and contours. The summary measures presented in this paper
allow decision-makers to explicitly trade off expected return on investment with the risk of re-
turn at different relative and absolute threshold values for multiple outcomes.
Table 3 contrasts and summarises suggested graphical representation and summary mea-
sures for informing societal decision making when comparing two strategies and multiple
strategies with single and multiple effects.
Fig 6. Cost-effectiveness acceptability planes (two dimensional representation).
doi:10.1371/journal.pone.0115544.g006
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Contemporary economic evaluation methods are limited when comparing interventions
with multiple outcomes. Although CCA explicitly presents multiple outcomes and costs, they
are considered independently rather than jointly when allowing for uncertainty. Also, this ap-
proach does not allow for differences in ENB. Multiple outcomes comparison in CDU space re-
tains advantages of CCA in comparing multiple outcomes while additionally allowing rigorous
assessment of joint uncertainty across multiple outcomes and estimation of differences in ENL.
Furthermore, the ability of the methods developed to allow for different relative preferences
[42] is also valuable for informing individual patient and population level decisions
under uncertainty.
Cost-benefit analysis could include multiple effects. However, this approach is limited by
the difficulties of valuing health outcomes in monetary terms and the influence of ability to pay
on willingness to pay [43, 44]. Multiple outcomes comparison in CDU space allows explicit
Table 3. Best presentation and summary measures for informing risk-neutral and somewhat risk
averse decision making [25].
Risk preferences
Scenario Risk-neutral# Somewhat risk averse^
Two strategies & one
effect
CE plane CE plane
INB curve INB curves & CI
ENL curves &
frontier
CEA curve
ENL curves & frontier
Two strategies &
multiple effects
Frontier in CDU
space$
Frontier in CDU space$
Threshold
regions
Threshold regions
ENL planes and
contour
ENL planes and contour
CEAP
Multiple strategies & a
single effect
CDU plane CDU plane
ENL curves &
frontier
ENL curves and frontier
Trade-offs in discrete threshold regions where they arise
between minimising ENL and P(min NL) taken from relevant
bilateral CEA curves
Multiple strategies &
multiple effects
Frontier in CDU
space$
Frontier in CDU space$
Threshold
regions
Threshold regions
ENL planes &
contour
ENL planes and contour
Trade-offs in discrete threshold regions where they arise
between minimising ENL and P(min NL) taken from relevant
bilateral CEAPs
# objective is to maximise ENB;
^ trade-offs can arise over discrete threshold regions between the strategy maximising ENB and strategies
with a higher probability of maximising NB relative to that strategy;
$ for a maximum of two effects; CDU = cost-disutility; CE = cost-effectiveness; CEA = cost-effectiveness
acceptability; CEAP = cost-effectiveness acceptability plane; CI = confidence intervals; ENL = expected net
loss; INB = incremental net monetary benefit; P(min NL) = probability of minimising net loss
doi:10.1371/journal.pone.0115544.t003
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exploration of relative and absolute monetary values for multiple outcomes on preferred strate-
gies. Further, this approach permits robust analysis of the impact of uncertainty around mone-
tary threshold values with ENL contours.
Cost-effectiveness analysis is limited by a uni-dimensional measure, where choice of out-
come can give rise to outcome selection bias as illustrated in this paper. Cost-utility analysis
(CUA) is limited by narrowly defined health-related QOL domains in the commonly applied
generic MAUIs which exclude important domains unable to be integrated with patient survival
in complex disease areas such as palliative care, e.g. utility from preparing for death [45], carer
and family impacts and non-health outcomes [46]. The novel methodology presented in this
paper enables simultaneous evaluation of such diverse domains of effect.
Previously there have been only a few attempts to develop specific methods to evaluate and
present costs and multiple outcomes under uncertainty in an explicit manner. Bjorner and
Keiding [47] proposed a relative cost-effectiveness measure. Negrin and Vazquez-Polo [48]
presented an alternative Bayesian cost-effectiveness framework. The Bjorner and Keiding ap-
proach compares the performance of each intervention relative to the worst performing inter-
vention in a set of interventions using DEA [47]. However, their relative cost-effectiveness
measure does not inform decisions between non-dominated interventions, nor allow consider-
ation of stochastic uncertainty, or allow estimation of the probability of maximising expected
NB. The Bayesian methodology [48] graphically represents the intervention most likely to
maximise NB at various combinations of threshold values for multiple outcomes using a cost-
effectiveness acceptability frontier. Geometrically, this is similar to the CEAP derived from
comparison in CDU space. However, neither of these previous approaches provides summary
measures for quantifying differences in ENB between strategies under uncertainty, which is
the critical comparison required to inform risk-neutral or somewhat risk-averse decision
making [25, 41].
In this paper, the NBCT is applied with CEA to inform health technology assessment. Simi-
larly, the novel approach to multiple outcome comparison illustrated here could be applied to
compare multiple outcomes, objectives and facets of chronic disease management programs
[49], health promotion and disease prevention in complex community care settings [50–56].
Multiple aspects relevant to such comparisons might include self-management capability, co-
ordination and process aspects of care, network impacts and community uptake and ownership
of promotion interventions in complex settings. Other forms of multiple criteria decision anal-
ysis (MCDA) have been proposed to allow for multiple objectives and outcomes in some of
these settings [57, 58]. The NBCT [24–26] applied to multiple outcomes [59] would enable a
comparison of such multiple criteria consistent with maximising NB and is summarised with
ENL planes and contours. Unlike CEACs [58] and other transformations proposed, the ENL
planes and contour and ENL curves and frontiers [24] are consistent with differences in ENB.
This is particularly important given the primary importance under the Arrow-Lind theorem
[41] to compare differences in ENB and avoid confounding of relevant probabilities between
potentially optimal strategies that arises with multiple strategy CEACs in multiple strategy
comparisons [25]. Consequently, application of the proposed methodology in alternative
health promotion and prevention settings as well as disease areas, with their associated multiple
effects or criteria of interest for decision making are suggested as valuable. Applying the values
and preferences of individuals, different patient populations and societal decision makers
across jurisdictions for relevant multiple outcomes should be considered in future research to
further demonstrate the flexibility of this approach.
If the threshold values for effects in NB are to aid optimization of health outcomes from a
fixed budget then assuming the new technology or strategy has net costs the threshold value
should reflect the opportunity cost of reimbursement in adopting and financing the new
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service, technology or strategy [22, 32–34]. That is, the opportunity cost of reimbursing a new
technology is the most cost-effective expansion of existing services financed by contraction or
displacement of the least cost-effective service. The opportunity cost and threshold value
should be estimated allowing for characteristic allocative and displacement inefficiency in
health systems where the least cost-effective program in contraction (ICER =m) has a higher
ICER than the most cost-effective program in expansion (ICER = n) and displaced services
(ICER = d). The health shadow price derived by Pekarsky [34] (see Equation 8), allows for allo-
cative inefficiency (n<m) and displacement inefficiency (d<m) to reflect the opportunity
cost of best alternative adoption and financing actions in reimbursing new technology.
bc ¼
1
n
þ 1
d
þ 1
m
 1
Equation 8
The health shadow price threshold has a value of n, equivalent to the ICER of the most cost-
effective expansion of current programs if displacement is efficient (d =m), but is less than n
where displacement is suboptimal (d<m), reflecting the potential to improve displacement as
well as adoption actions [22]. In the case of multiple effects the associated threshold values
should be determined by their relevant health shadow prices as these represent the best alterna-
tive way for societal decision makers to achieve each outcome.
Multiple outcomes analysis in CDU space with use of the ENL contour as a summary mea-
sure while highlighting which strategy optimises ENB across potential threshold values for ef-
fects also naturally represents the expected value of perfect information [24, 25]. This provides
a starting point to consider use of value of information (VOI) methods to inform decisions
under uncertainty of whether undertaking further research is optimal. VOI methods aid opti-
misation of trial design in maximising expected return on investment from further research,
comparing the expected value relative to expected cost of additional research allowing for rele-
vant decision contexts [16, 21, 60, 61].
Limitations
Despite distinct advantages over existing methods for multiple outcome comparisons, there are
some issues to consider. While multiple outcomes comparison presented in CDU space enables
flexible and robust comparison under uncertainty, as with other multiple outcome approaches
issues of valuation and trade-offs between outcomes arise. Relative decision-maker threshold
values are required for funding or policy decisions in any jurisdiction of interest for their popu-
lation, practice, and preferences conditional on the budget constrained decision context wheth-
er based on cost-effectiveness, cost-utility or cost-benefit analyses. Multiple outcomes
comparison in CDU space, unlike alternative methods, enables explicit joint comparison of
costs and multiple outcomes prior to valuation and encourages explicit valuation and acknowl-
edgment of trade-offs between outcomes in the decision-making process. These issues are
particularly important where the maximand for cost-effectiveness analysis is not stated. In
cost-utility analyses, multiple threshold valuation also occurs for different outcomes or do-
mains within the MAUI but is less explicit or readily identified. Generally, valuing effects
should, as with the proposed approach, be explicit to enable appropriate translation of impacts
to decision making in different contexts.
The methodology presented can be applied to any number of strategies and any number
and types of outcome measures. However, whilst graphical presentation for comparison is fea-
sible in two- and three-dimensional space, further dimensions cannot be easily graphically rep-
resented in ways that are currently familiar in societal decision-making. Similarly, knowledge
of frontier methods such as DEA may be restricted to those with mathematical or economic
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backgrounds and hence application of these methods to fully exploit the benefits of multiple
outcomes comparison in CDU space could require educational support to aid knowledge trans-
lation. Despite this, the general formulae promote transferability of the method across different
populations and jurisdictions given different values can be imputed for each outcome depend-
ing on perspective and context.
Further research is required to exploit the societal decision making advantages of robustly
comparing multiple outcomes and multiple strategies in CDU space illustrated in this paper.
Application of the approach in alternative disease areas, with different numbers of multiple ef-
fects and/or strategies would be particularly valuable. The views of bodies and individuals in-
volved in societal-decision making on the relative merits of alternative presentation and
summary measures for evaluating the cost-effectiveness of interventions with multiple effects
could also be sought to explore the interface between theoretical and practical advantages and
lead to further development of the methodology in practice.
Conclusion
Better methods are needed to compare the cost effectiveness of alternative strategies with mul-
tiple outcomes under uncertainty in complex service delivery areas such as palliative care. On
the cost-effectiveness plane analysis is restricted to one outcome and not all outcome domains
can be integrated with survival in estimating QALYs. Furthermore, cost-consequences analyses
fail to allow for joint uncertainty across outcomes. Comparison in CDU space with ENL planes,
contours and CEAPS have been shown to allow presentation of uncertainty across multiple
outcomes with summary measures quantifying differences in ENB and the probability of maxi-
mising ENB at any given set of threshold values for multiple outcomes. Incorrect inferences are
avoided using these presentation and summary measures and risk-neutral or somewhat risk-
averse societal decision making better informed, while the potential value of future research
(EVPI) is also estimated. In summary, analysis in CDU space provides a readily accessible and
systematic way to compare multiple outcomes in CEA and NB assessment under uncertainty.
In comparing multiple strategies a more robust picture of the likely trade-offs between costs
and benefits, the consequences of funding decisions and the need for future research reduces
inferential errors and better informs societal decisions [16, 21, 62, 63].
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